BACKGROUND: Transfusion-dependency affects the natural history of myelodysplastic syndromes. Secondary iron overload may concur to this effect. The relative impact of these factors on the outcome of patients with myelodysplastic syndrome receiving allogeneic stem-cell transplantation remains to be clarified. DESIGN AND METHODS: We retrospectively evaluated the prognostic effect of transfusion history and iron overload on the post-transplantation outcome of 357 patients with myelodysplastic syndrome reported to the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) registry between 1997 and 2007. RESULTS: Transfusion-dependency was independently associated with reduced overall survival (hazard ratio=1.48, P=0.017) and increased non-relapse mortality (hazard ratio=1.68, P=0.024). The impact of transfusion-dependency was noted only in patients receiving myeloablative conditioning (overall survival: hazard ratio=1.76, P=0.003; non-relapse mortality: hazard ratio=1.70, P=0.02). There was an inverse relationship between transfusion burden and overall survival after transplantation (P=0.022); the outcome was significantly worse in subjects receiving more than 20 red cell units. In multivariate analysis, transfusion-dependency was found to be a risk factor for acute graft-versus-host disease (P=0.04). Among transfusion-dependent patients undergoing myeloablative allogeneic stem cell transplantation, pre-transplantation serum ferritin level had a significant effect on overall survival (P=0.01) and non-relapse mortality (P=0.03). This effect was maintained after adjusting for transfusion burden and duration, suggesting that the negative effect of transfusion history on outcome might be determined at least in part by iron overload. CONCLUSIONS: Pre-transplantation transfusion history and serum ferritin have significant prognostic value in patients with myelodysplastic syndrome undergoing myeloablative allogeneic stem cell transplantation, inducing a significant increase of non-relapse mortality. These results indicate that transfusion history should be considered in transplantation decision-making in patients with myelodysplastic syndrome.
BACKGROUND: Transfusion-dependency affects the natural history of myelodysplastic syndromes. Secondary iron overload may concur to this effect. The relative impact of these factors on the outcome of patients with myelodysplastic syndrome receiving allogeneic stem-cell transplantation remains to be clarified. DESIGN AND METHODS: We retrospectively evaluated the prognostic effect of transfusion history and iron overload on the post-transplantation outcome of 357 patients with myelodysplastic syndrome reported to the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) registry between 1997 and 2007. RESULTS: Transfusion-dependency was independently associated with reduced overall survival (hazard ratio=1.48, P=0.017) and increased non-relapse mortality (hazard ratio=1.68, P=0.024). The impact of transfusion-dependency was noted only in patients receiving myeloablative conditioning (overall survival: hazard ratio=1.76, P=0.003; non-relapse mortality: hazard ratio=1.70, P=0.02). There was an inverse relationship between transfusion burden and overall survival after transplantation (P=0.022); the outcome was significantly worse in subjects receiving more than 20 red cell units. In multivariate analysis, transfusion-dependency was found to be a risk factor for acute graft-versus-host disease (P=0.04). Among transfusion-dependent patients undergoing myeloablative allogeneic stem cell transplantation, pre-transplantation serum ferritin level had a significant effect on overall survival (P=0.01) and non-relapse mortality (P=0.03). This effect was maintained after adjusting for transfusion burden and duration, suggesting that the negative effect of transfusion history on outcome might be determined at least in part by iron overload. CONCLUSIONS: Pre-transplantation transfusion history and serum ferritin have significant prognostic value in patients with myelodysplastic syndrome undergoing myeloablative allogeneic stem cell transplantation, inducing a significant increase of non-relapse mortality. These results indicate that transfusion history should be considered in transplantation decision-making in patients with myelodysplastic syndrome.
Authors: B D Cheson; J M Bennett; H Kantarjian; A Pinto; C A Schiffer; S D Nimer; B Löwenberg; M Beran; T M de Witte; R M Stone; M Mittelman; G F Sanz; P W Wijermans; S Gore; P L Greenberg Journal: Blood Date: 2000-12-01 Impact factor: 22.113
Authors: David Bowen; Dominic Culligan; Simon Jowitt; Stephen Kelsey; Ghulam Mufti; David Oscier; Jane Parker Journal: Br J Haematol Date: 2003-01 Impact factor: 6.998
Authors: T de Witte; J Hermans; J Vossen; A Bacigalupo; G Meloni; N Jacobsen; T Ruutu; P Ljungman; A Gratwohl; V Runde; D Niederwieser; A van Biezen; A Devergie; J Cornelissen; J P Jouet; R Arnold; J Apperley Journal: Br J Haematol Date: 2000-09 Impact factor: 6.998
Authors: H J Deeg; H M Shulman; J E Anderson; E M Bryant; T A Gooley; J T Slattery; C Anasetti; A Fefer; R Storb; F R Appelbaum Journal: Blood Date: 2000-02-15 Impact factor: 22.113
Authors: Jorge Sierra; Waleska S Pérez; Ciril Rozman; Enric Carreras; John P Klein; J Douglas Rizzo; Stella M Davies; Hillard M Lazarus; Christopher N Bredeson; David I Marks; Carmen Canals; Marc A Boogaerts; John Goldman; Richard E Champlin; Armand Keating; Daniel J Weisdorf; Theo M de Witte; Mary M Horowitz Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: Emilio Paolo Alessandrino; Sergio Amadori; Giovanni Barosi; Mario Cazzola; Alberto Grossi; Lucio N Liberato; Franco Locatelli; Monia Marchetti; Enrica Morra; Paolo Rebulla; Giuseppe Visani; Sante Tura Journal: Haematologica Date: 2002-12 Impact factor: 9.941
Authors: Razvan Diaconescu; Christopher R Flowers; Barry Storer; Mohamed L Sorror; Michael B Maris; David G Maloney; Brenda M Sandmaier; Rainer Storb Journal: Blood Date: 2004-05-18 Impact factor: 22.113
Authors: Corey S Cutler; Stephanie J Lee; Peter Greenberg; H Joachim Deeg; Waleska S Pérez; Claudio Anasetti; Brian J Bolwell; Mitchell S Cairo; Robert Peter Gale; John P Klein; Hillard M Lazarus; Jane L Liesveld; Philip L McCarthy; Gustavo A Milone; J Douglas Rizzo; Kirk R Schultz; Michael E Trigg; Armand Keating; Daniel J Weisdorf; Joseph H Antin; Mary M Horowitz Journal: Blood Date: 2004-03-23 Impact factor: 22.113
Authors: Philippe Armand; Haesook T Kim; Johanna M Virtanen; Riitta K Parkkola; Maija A Itälä-Remes; Navneet S Majhail; Linda J Burns; Todd DeFor; Bryan Trottier; Uwe Platzbecker; Joseph H Antin; Martin Wermke Journal: Biol Blood Marrow Transplant Date: 2014-04-24 Impact factor: 5.742
Authors: M Tanaka; H Kanamori; K Matsumoto; T Tachibana; A Numata; K Ohashi; T Kobayashi; C Nakaseko; Y Kanda; E Yamazaki; S Fujisawa; J Ooi; T Sakura; N Aotsuka; M Onoda; S Machida; J Kato; K Usuki; R Watanabe; J Taguchi; S Yano; T Saito; S Takahashi; H Sakamaki; S Okamoto Journal: Bone Marrow Transplant Date: 2015-03-02 Impact factor: 5.483
Authors: Philippe Armand; Marie-Michele Sainvil; Haesook T Kim; Joanna Rhodes; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Ellis J Neufeld; Raymond Y Kwong; Robert J Soiffer; Joseph H Antin Journal: Am J Hematol Date: 2012-04-04 Impact factor: 10.047